Chemical formula: C₂₆H₂₈N₂ Molecular mass: 368.524 g/mol PubChem compound: 2761
Cinnarizine has been shown to be a non-competitive antagonist of the smooth muscle contractions caused by various vasoactive agents including histamine. Cinnarizine also acts on vascular smooth muscle by selectively inhibiting the calcium influx into depolarised cells, thereby reducing the availability of free Ca2+ ions for the induction and maintenance of contraction.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N07CA02 | Cinnarizine | N Nervous system → N07 Other nervous system drugs → N07C Antivertigo preparations → N07CA Antivertigo preparations |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| STUGERON Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Cinnarizine is an active ingredient of these brands:
Austria (AT)
Croatia (HR)
Finland (FI)
Hong Kong (HK)Israel (IL)Netherlands (NL)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
